<DOC>
	<DOC>NCT00361868</DOC>
	<brief_summary>Under conditions of first-line drug treatment in antidiabetic drug na√Øve/drug free patients with type 2 diabetes mellitus and dyslipidemia, to show that :- the efficacy of a fixed combination (FC) of fenofibrate and metformin on glycemic control is not inferior to that of rosiglitazone and the efficacy of FC of fenofibrate and metformin on triglyceride control is superior to that of rosiglitazone.</brief_summary>
	<brief_title>Fenofibrate and Metformin Fixed Combination vs Rosiglitazone - FAME ROSI</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Glucose Metabolism Disorders</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>Patient with Type 2 diabetes mellitus and dyslipidemia inadequately controlled with lifestyle modifications. Type 1 diabetes.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Treatment of Dyslipidemia and of Type 2 Diabetes Mellitus</keyword>
</DOC>